Holders — by stockHoldings — by fund
NEA Management Company, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001512848
$1.59B
disclosed book value
26
positions
15.5%
largest position share
Positions, as of 2026-06-30
top 26 of 26 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | TRVITrevi Therapeutics, Inc. | 13.2M | $246.6M | 15.5% |
| 2 | MBXMBX Biosciences, Inc. | 3.6M | $199.5M | 12.6% |
| 3 | GLUEMonte Rosa Therapeutics, Inc. | 7.7M | $186.2M | 11.7% |
| 4 | CELCCelcuity Inc. | 1.7M | $179.0M | 11.3% |
| 5 | SGPSpyglass Pharma, Inc. | 7.4M | $164.6M | 10.4% |
| 6 | SVRASavara, Inc. | 24.5M | $150.7M | 9.5% |
| 7 | ZBIOZenas BioPharma, Inc. | 4.0M | $102.1M | 6.4% |
| 8 | COURCoursera, Inc. | 12.9M | $72.6M | 4.6% |
| 9 | AUPHAurinia Pharmaceuticals, Inc. | 4.0M | $67.4M | 4.2% |
| 10 | CRISPR Therapeutics AG | 1.1M | $57.7M | 3.6% |
| 11 | ORICORIC Pharmaceuticals, Inc. | 4.1M | $44.6M | 2.8% |
| 12 | PHATPhathom Pharmaceuticals, Inc. | 2.0M | $21.3M | 1.3% |
| 13 | KRROKorro Bio, Inc. | 1.3M | $17.1M | 1.1% |
| 14 | ASNSUSDX4 Pharmaceuticals, Inc. | 3.2M | $15.1M | 1% |
| 15 | CSBRChampions Oncology, Inc. | 1.7M | $10.6M | 0.7% |
| 16 | NKTXNkarta, Inc. | 3.6M | $10.1M | 0.6% |
| 17 | CVRXCVRx, Inc. | 2.0M | $10.0M | 0.6% |
| 18 | BDTXBlack Diamond Therapeutics, Inc. | 4.4M | $8.2M | 0.5% |
| 19 | KPTIKaryopharm Therapeutics Inc. | 576,780 | $5.6M | 0.4% |
| 20 | IVAInventiva SA | 1.5M | $5.5M | 0.3% |
| 21 | LONALeonaBio, Inc. | 464,398 | $4.3M | 0.3% |
| 22 | Senti Biosciences, Inc. | 3.8M | $4.2M | 0.3% |
| 23 | MRKRMarker Therapeutics, Inc. | 1.6M | $2.4M | 0.2% |
| 24 | OKUROnKure Therapeutics, Inc. | 478,548 | $2.2M | 0.1% |
| 25 | IMAImageneBio, Inc. | 50,005 | $295,030 | 0% |
| 26 | GOSSGossamer Bio, Inc. | 1.0M | $164,600 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.